» Articles » PMID: 33362713

Activation of Melanocortin Receptors As a Potential Strategy to Reduce Local and Systemic Reactions Induced by Respiratory Viruses

Overview
Specialty Endocrinology
Date 2020 Dec 28
PMID 33362713
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical hallmarks of infections caused by critical respiratory viruses consist of pneumonia, which can progress to acute lung injury (ALI), and systemic manifestations including hypercoagulopathy, vascular dysfunction, and endotheliitis. The disease outcome largely depends on the immune response produced by the host. The bio-molecular mechanisms underlying certain dire consequences of the infection partly arise from an aberrant production of inflammatory molecules, an event denoted as "cytokine storm". Therefore, in addition to antiviral therapies, molecules able to prevent the injury caused by cytokine excess are under investigation. In this perspective, taking advantage of melanocortin peptides and their receptors, components of an endogenous modulatory system that exerts marked anti-inflammatory and immunomodulatory influences, could be an effective therapeutic strategy to control disease evolution. Exploiting the melanocortin system using natural or synthetic ligands can form a realistic basis to counteract certain deleterious effects of respiratory virus infections. The central and peripheral protective actions exerted following melanocortin receptor activation could allow dampening the harmful events that trigger the cytokine storm and endothelial dysfunction while sustaining the beneficial signals required to elicit repair mechanisms. The long standing evidence for melanocortin safety encourages this approach.

Citing Articles

Anti-Melanogenic Effects of L-Theanine on B16F10 Cells and Zebrafish.

Yu C, Pang H, Run Z, Wang G Molecules. 2025; 30(4).

PMID: 40005265 PMC: 11858779. DOI: 10.3390/molecules30040956.


Effect of early administration of tetracosactide on mortality and host response in critically ill patients requiring rescue surgery: a sensitivity analysis of the STOPSHOCK phase 3 randomized controlled trial.

Noera G, Bertolini A, Calza L, Gori M, Pitino A, DArrigo G Mil Med Res. 2024; 11(1):56.

PMID: 39160574 PMC: 11331742. DOI: 10.1186/s40779-024-00555-2.


Alpha-melanocyte-stimulating hormone contributes to an anti-inflammatory response to lipopolysaccharide.

Reynolds R, Fan R, Tinajero A, Luo X, Huen S, Fujikawa T Mol Metab. 2024; 87:101986.

PMID: 38992428 PMC: 11362619. DOI: 10.1016/j.molmet.2024.101986.


Acthar Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence.

Kaplan J, Askanase A, Chu D, Abdellatif A, Basu D, Mirsaeidi M Clin Drug Investig. 2023; 43(10):739-761.

PMID: 37792273 PMC: 10575998. DOI: 10.1007/s40261-023-01303-5.


Literature-Based Discovery to Elucidate the Biological Links between Resistant Hypertension and COVID-19.

Kartchner D, McCoy K, Dubey J, Zhang D, Zheng K, Umrani R Biology (Basel). 2023; 12(9).

PMID: 37759668 PMC: 10526006. DOI: 10.3390/biology12091269.

References
1.
Varga Z, Flammer A, Steiger P, Haberecker M, Andermatt R, Zinkernagel A . Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234):1417-1418. PMC: 7172722. DOI: 10.1016/S0140-6736(20)30937-5. View

2.
Stockman L, Bellamy R, Garner P . SARS: systematic review of treatment effects. PLoS Med. 2006; 3(9):e343. PMC: 1564166. DOI: 10.1371/journal.pmed.0030343. View

3.
Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim W . Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev. 2019; 2:CD010406. PMC: 6387789. DOI: 10.1002/14651858.CD010406.pub3. View

4.
Lonati C, Bassani G, Brambilla D, Leonardi P, Carlin A, Faversani A . Influence of ex vivo perfusion on the biomolecular profile of rat lungs. FASEB J. 2018; 32(10):5532-5549. DOI: 10.1096/fj.201701255R. View

5.
Getting S, Christian H, Lam C, Gavins F, Flower R, Schioth H . Redundancy of a functional melanocortin 1 receptor in the anti-inflammatory actions of melanocortin peptides: studies in the recessive yellow (e/e) mouse suggest an important role for melanocortin 3 receptor. J Immunol. 2003; 170(6):3323-30. DOI: 10.4049/jimmunol.170.6.3323. View